Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 10680 matches for

Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for £3.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.

Histology and magnetic resonance images from a mouse with breast cancer brain metastases, injected intravenously 2 hours previously with a TNFR1-selective mutant TNF protein. 3 items in the picture: Cresyl violet stained brain section showing location of a micrometastasis. Adjacent brain section stained with Hanker-Yates demonstrates HRP extravasation (brown staining) and, hence, BBB breakdown selectively at the site of metastasis. Post-contrast (gadolinium-DTPA) image from the same mouse showing extravasation of contrast at the metastatic site (hyperintensity) confirming local BBB breakdown. Note, the BBB remains intact in the rest of the brain.
Figure caption: Histology and magnetic resonance images from a mouse with breast cancer brain metastases, injected intravenously 2 hours previously with a TNFR1-selective mutant TNF protein. (A) Cresyl violet stained brain section showing location of a micrometastasis (boxed region and inset). (B) Adjacent brain section stained with Hanker-Yates demonstrates HRP extravasation (brown staining) and, hence, BBB breakdown selectively at the site of metastasis. (C) Post-contrast (gadolinium-DTPA) image from the same mouse showing extravasation of contrast at the metastatic site (hyperintensity) confirming local BBB breakdown. Note, the BBB remains intact in the rest of the brain.

SYMPLIFY Letter (upload Oct 24)

SYMPLIFY_ParticipantLetterAdditionalFollowUp_V519Aug24FINAL.pdf (184 KB)

SYMPLIFY_ParticipantLetterAdditionalFollowUpV519Aug24FINAL.pdf

SYMPLIFY_ParticipantLetterAdditionalFollowUpV519Aug24FINAL.pdf (184 KB)

SYMPLIFY_ParticipantLetterAdditionalFollowUpV519Aug24FINAL.pdf

SYMPLIFY_ParticipantLetterAdditionalFollowUpV519Aug24FINAL.pdf (184 KB)

Edit your oncology website profile

Oncology_-_Editing_Your_Web_Profile_SOP_-_v3_Feb_2020_.pdf (617 KB)

Anti-Bullying Information for Staff and Students

AntiBullyingInformationforStaffandStudents.pdf (392 KB)

Common Bullying Questions Answered

CommonBullyingQuestionsAnswered.pdf (381 KB)

SYMPLIFY NHS Digital Letter

SYMPLIFY_ParticipantLetterDARSNIC661736Y2Q9R_v1.1_10Nov2022_signed24Nov2022.pdf (138 KB)

TestdocforSYMPLIFY.docx

TestdocforSYMPLIFY.docx (11 KB)

University of Oxford, Department of Oncology, Athena SWAN Silver Application.pdf

This document is the Department of Oncology's application for an Athena SWAN silver level award.

University of Oxford, Department of Oncology, Athena SWAN Silver Application.pdf (2 MB)

University of Oxford, Department of Oncology 2020 Athena SWAN Action Plan.pdf

This document identifies the Department's key actions needed to realise its aims to further promote gender equality in higher education and research.

University of Oxford, Department of Oncology 2020 Athena SWAN Action Plan.pdf (373 KB)

Preclinical_SRF_MR-IGRT.pptx

Preclinical_SRF_MR-IGRT.pptx (17 MB)

TeamInductionChecklistNov19.pdf

TeamInductionChecklistNov19.pdf (110 KB)

Team Induction Checklist.pdf

Team Induction Checklist.pdf (107 KB)

OpenClinica Site Data Entry Guide.pdf

V4.0 Sep 2018

OCTO_OpenClinicaSiteDataEntryGuide_V4.0_19Sep2018.pdf (2 MB)

IPI-GLIO Study Schema.jpg

IPI-GLIO Study Schema.jpg (108 KB)

Similar stories

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).

Subashan Vadibeler wins 2024 Lasker Essay Contest

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Gulnar Abdullayeva receives an Azerbaijan Presidential Award for Youth 2024

Robert Watson Awarded ACP McElwain and Presidents Prize

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.